SREBF1 and metabolic dysfunction-associated steatotic liver disease: In particular, the application of proteomic and metabolomic profiling technologies to NAFLD plasma might contribute to identify any circulating factor(s) (microRNA, extracellular vesicles), whereas, in vitro experiments could be organized to increase the knowledge about the intracellular mechanisms (SREBP-1c, PPARγ, inflammasome molecules, AMPK).